pioglitazone has been researched along with Coronary Restenosis in 21 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications." | 9.14 | Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009) |
| "This study investigates whether pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with metabolic syndrome (MS) using intravascular ultrasound (IVUS)." | 9.12 | Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. ( Katayama, T; Kawakami, M; Kubo, N; Kuroki, M; Momomura, S; Saito, M; Tsuboi, K; Ueba, H; Yasu, T, 2007) |
| "The study population included 121 DM patients with coronary artery disease and they were randomly assigned to 60 patients taking 15 mg of pioglitazone daily in addition to their diabetic medications and 61 patients with placebo after the index procedure with drug-eluting stents (DESs)." | 5.17 | Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. ( Cha, KS; Choi, JH; Hong, TJ; Kim, BW; Kim, SP; Lee, HC; Lee, HW; Oh, JH; Park, JH; Park, JS; Song, S; Yang, MJ, 2013) |
| "Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications." | 5.14 | Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009) |
| "This study investigates whether pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with metabolic syndrome (MS) using intravascular ultrasound (IVUS)." | 5.12 | Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. ( Katayama, T; Kawakami, M; Kubo, N; Kuroki, M; Momomura, S; Saito, M; Tsuboi, K; Ueba, H; Yasu, T, 2007) |
| " Pioglitazone has antiatherogenic property through the inhibition of inflammation." | 3.74 | Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. ( Daida, H; Ikeda, E; Kajimoto, K; Kasai, T; Kubota, N; Miyauchi, K; Sumiyoshi, K; Yokoyama, T, 2008) |
| "Pioglitazone treatment might suppress in-stent neointimal proliferation and reduce incidence of TLR after PCI in patients with T2DM." | 2.74 | A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). ( Fitzgerald, PJ; Honda, Y; Ikeno, F; Ito, A; Kataoka, T; Kobayashi, Y; Okura, H; Sakanoue, Y; Shimeno, K; Taguchi, H; Takagi, T; Tamita, K; Toda, I; Waseda, K; Yamamuro, A; Yamasaki, M; Yanagi, S; Yoshikawa, J; Yoshiyama, M, 2009) |
| "The treatment with pioglitazone in type 2 diabetic patients significantly reduced leptin." | 2.72 | A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. ( Fukui, T; Itoh, S; Katagiri, T; Kawamura, K; Konno, N; Kusuyama, T; Nishio, K; Sakurai, M; Shigemitsu, M, 2006) |
| "Pioglitazone treatment seems to have more beneficial effects than rosiglitazone and no significantly increased cardiovascular risk was detected for both agents." | 2.55 | Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials. ( Chen, S; Dai, J; Hua, J; Mao, W; Qiu, Y; Xu, X; Zhou, X; Zhu, M, 2017) |
| "The treatment of pioglitazone was associated with a reduction in ISR and TLR in T2DM patients suffering from PCI, except the incidence of MACE." | 2.53 | Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis. ( Chen, L; Qi, GX; Shi, LY; Tian, W; Zhao, SJ; Zhong, ZS, 2016) |
| "The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States." | 2.44 | PPARgamma agonists and coronary atherosclerosis. ( Chilton, R; Sulistio, MS; Thukral, N; Zion, A, 2008) |
| "Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors." | 2.42 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, X | 1 |
| Chen, S | 1 |
| Zhu, M | 1 |
| Hua, J | 1 |
| Dai, J | 1 |
| Xu, X | 1 |
| Qiu, Y | 1 |
| Mao, W | 1 |
| Lee, HW | 1 |
| Lee, HC | 1 |
| Kim, BW | 1 |
| Yang, MJ | 1 |
| Park, JS | 1 |
| Oh, JH | 1 |
| Choi, JH | 1 |
| Cha, KS | 1 |
| Hong, TJ | 1 |
| Kim, SP | 1 |
| Song, S | 1 |
| Park, JH | 2 |
| Zhang, MD | 1 |
| Zhang, YH | 1 |
| Zhu, EJ | 1 |
| Qiao, SB | 1 |
| Lv, SZ | 1 |
| Zhao, QM | 1 |
| Zhao, SJ | 1 |
| Zhong, ZS | 1 |
| Qi, GX | 1 |
| Shi, LY | 1 |
| Chen, L | 1 |
| Tian, W | 1 |
| Kaneda, H | 1 |
| Shiono, T | 1 |
| Miyashita, Y | 1 |
| Takahashi, S | 1 |
| Taketani, Y | 1 |
| Domae, H | 1 |
| Matsumi, J | 1 |
| Mizuno, S | 1 |
| Minami, Y | 1 |
| Sugitatsu, K | 1 |
| Saito, S | 1 |
| Takagi, T | 2 |
| Okura, H | 1 |
| Kobayashi, Y | 1 |
| Kataoka, T | 1 |
| Taguchi, H | 1 |
| Toda, I | 1 |
| Tamita, K | 2 |
| Yamamuro, A | 2 |
| Sakanoue, Y | 1 |
| Ito, A | 1 |
| Yanagi, S | 1 |
| Shimeno, K | 1 |
| Waseda, K | 1 |
| Yamasaki, M | 1 |
| Fitzgerald, PJ | 1 |
| Ikeno, F | 1 |
| Honda, Y | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 2 |
| Nissen, SE | 1 |
| Hong, SJ | 1 |
| Kim, ST | 1 |
| Kim, TJ | 1 |
| Kim, EO | 1 |
| Ahn, CM | 1 |
| Kim, JS | 1 |
| Lee, KM | 1 |
| Lim, DS | 1 |
| Patel, D | 1 |
| Walitt, B | 1 |
| Lindsay, J | 1 |
| Wilensky, RL | 1 |
| Yokoi, H | 1 |
| Yamabe, K | 1 |
| Katayama, M | 1 |
| Mizoguchi, S | 1 |
| Ibuki, M | 1 |
| Tani, T | 1 |
| Tanabe, K | 1 |
| Nagai, K | 1 |
| Shiratori, K | 1 |
| Morioka, S | 1 |
| Roberts, AW | 1 |
| Thomas, A | 1 |
| Rees, A | 1 |
| Evans, M | 1 |
| Marx, N | 1 |
| Wöhrle, J | 1 |
| Nusser, T | 1 |
| Walcher, D | 1 |
| Rinker, A | 1 |
| Hombach, V | 1 |
| Koenig, W | 1 |
| Höher, M | 1 |
| Schömig, A | 1 |
| Kastrati, A | 1 |
| Wessely, R | 1 |
| Nishio, K | 1 |
| Sakurai, M | 1 |
| Kusuyama, T | 1 |
| Shigemitsu, M | 1 |
| Fukui, T | 1 |
| Kawamura, K | 1 |
| Itoh, S | 1 |
| Konno, N | 1 |
| Katagiri, T | 1 |
| Joner, M | 1 |
| Farb, A | 1 |
| Cheng, Q | 1 |
| Finn, AV | 1 |
| Acampado, E | 1 |
| Burke, AP | 1 |
| Skorija, K | 1 |
| Creighton, W | 1 |
| Kolodgie, FD | 1 |
| Gold, HK | 1 |
| Virmani, R | 1 |
| Katayama, T | 1 |
| Ueba, H | 1 |
| Tsuboi, K | 1 |
| Kubo, N | 1 |
| Yasu, T | 1 |
| Kuroki, M | 1 |
| Saito, M | 1 |
| Momomura, S | 1 |
| Kawakami, M | 1 |
| Douglas, JS | 1 |
| Kasai, T | 1 |
| Miyauchi, K | 1 |
| Yokoyama, T | 1 |
| Kajimoto, K | 1 |
| Sumiyoshi, K | 1 |
| Kubota, N | 1 |
| Ikeda, E | 1 |
| Daida, H | 1 |
| Sulistio, MS | 1 |
| Zion, A | 1 |
| Thukral, N | 1 |
| Chilton, R | 1 |
8 reviews available for pioglitazone and Coronary Restenosis
| Article | Year |
|---|---|
Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; | 2017 |
Effect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trials.
Topics: Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Hypoglycemic Agents; Piog | 2014 |
Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Occlusion; Coronary Restenosis; | 2016 |
Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Resten | 2011 |
[Pioglitazone].
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetes Complications; Humans; Hypoglycemic Ag | 2011 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten | 2003 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease | 2007 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2008 |
8 trials available for pioglitazone and Coronary Restenosis
| Article | Year |
|---|---|
Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation.
Topics: Aged; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Hypoglycemi | 2013 |
Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; | 2009 |
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; California; Cell Proliferation; Coronary Angiog | 2009 |
Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Glucose; Cardiovascular Agents; Cell | 2010 |
Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; Coronary Angiography; Coronary Disease; Coronar | 2003 |
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Disease; C | 2005 |
A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.
Topics: Aged; Blood Pressure; Coronary Disease; Coronary Restenosis; Cytokines; Diabetes Mellitus, Type 2; D | 2006 |
Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
Topics: Coronary Restenosis; Coronary Vessels; Female; Follow-Up Studies; Humans; Hyperplasia; Hypoglycemic | 2007 |
5 other studies available for pioglitazone and Coronary Restenosis
| Article | Year |
|---|---|
Pioglitazone to reduce restenosis after bare-metal stent placement?
Topics: Angioplasty, Balloon, Coronary; Cell Proliferation; Coronary Restenosis; Diabetes Mellitus, Type 2; | 2009 |
[Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
Topics: Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Thera | 2003 |
Prevention of restenosis by systemic drug therapy: back to the future?
Topics: Cilostazol; Controlled Clinical Trials as Topic; Coronary Restenosis; Double-Blind Method; Drug Admi | 2005 |
Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1.
Topics: Administration, Oral; Animals; Atherosclerosis; Cell Proliferation; Cells, Cultured; Chemokine CCL2; | 2007 |
Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting.
Topics: Animals; Chemokine CCL2; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Humans; Hypo | 2008 |